Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

627
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
627
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

891
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
891
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

954
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
954

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.

The Lancet. Microbe·2024
Same author

Use of fasting plasma glucose to determine the approach for diagnosing gestational diabetes mellitus.

Diabetes research and clinical practice·2023
Same author

Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort.

Journal of the American Heart Association·2023
Same author

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.

The Lancet. Respiratory medicine·2023
Same author

Pregnancy, pregnancy outcomes, and infant growth and development after recovery from Ebola virus disease in Liberia: an observational cohort study.

The Lancet. Global health·2023
Same author

Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza.

JCI insight·2023

相关实验视频

Updated: May 5, 2026

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

17.0K

主要风险因素作为致命和非致命冠心病事件的先例.

Philip Greenland1, Maria Deloria Knoll, Jeremiah Stamler

  • 1Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill, USA. p-greenland@northwestern.edu

JAMA
|August 21, 2003
PubMed
概括

大多数冠心病 (CHD) 患者都有主要的风险因素,如高胆固醇,血压,糖尿病或吸烟. 这项研究证实,在没有先前接触至少一个主要风险因素的人群中,CHD事件很少出现.

更多相关视频

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K
Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

272

相关实验视频

Last Updated: May 5, 2026

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

17.0K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K
Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

272

科学领域:

  • 心血管医学 心血管医学
  • 流行病学 流行病学
  • 公共卫生 公共卫生

背景情况:

  • 人们普遍认为,许多冠心病 (CHD) 患者缺乏主要的风险因素.
  • 之前的研究还没有系统地量化CHD患者对糖尿病,吸烟,高胆固醇或高血压等风险因素的暴露.

研究的目的:

  • 确定在患有冠状动脉心脏病 (CHD) 的人群中暴露于主要危险因素的流行率.

主要方法:

  • 分析了三个前性队列研究:芝加哥心脏协会检测项目,多重风险因素干预试验和弗雷明汉心脏研究.
  • 包括超过37万名参与者在21-30年内进行了跟踪.
  • 对致命性心脏病和非致命性心肌梗塞 (MI) 的评估与主要风险因素相关:总胆固醇≥240 mg/dL,静脉血压≥140 mm Hg,透气血压≥90 mm Hg,吸烟和糖尿病.

主要成果:

  • 暴露于至少一个主要的心脏病风险因素的风险在致命性心脏病的87%至100%之间.
  • 在40-59岁的致命性心血管疾病患者中,87%-94%的患者先前接触过至少一个主要的危险因素.
  • 对于非致命性心脏病发作,在92%的男性和87%的40-59岁女性中记录了先前暴露.

结论:

  • 对主要危险因素的暴露在患有冠状动脉心脏病 (CHD) 的个人中非常普遍.
  • 这些发现强调了评估所有主要风险因素对于CHD风险估计和预防的重要性.
  • 这些结果挑战了人们对心血管疾病事件经常发生在没有暴露于主要危险因素的个体的看法.